Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages

Journal of Liposome Research

Volumn 25, Issue 2, 2015, Pages 131-140

  Hattori, Yoshiyuki ^a   Yamashita, Jun ^a   Sakaida, Chisato ^a   Kawano, Kumi ^a   Yonemochi, Etsuo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Folate receptor; Folic acid; Liposomes; Tumor associated macrophages; Zoledronic acid

Indexed keywords

FOLATE RECEPTOR; FOLIC ACID; LIPOSOME; MACROGOL 2000; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; INBRED MOUSE STRAIN; KB CELL LINE; MACROPHAGE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DIPHOSPHONATES; FEMALE; FOLIC ACID; HUMANS; IMIDAZOLES; KB CELLS; LIPOSOMES; MACROPHAGES; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED;

EID: 84942937790     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2014.954128     Document Type: Article

References (35)

1. Antony AC. (1996). Folate receptors. Annu Rev Nutr 16:501-21.
2. Aparicio A, Gardner A, Tu Y., et al. (1998). In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12: 220-9.
3. Bacman D, Merkel S, Croner R., et al. (2007). TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer 7:156.
4. Bak SP, Walters JJ, Takeya M, et al (2007). Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res 67:4783-9.
5. Bingle L, Brown NJ, Lewis CE (2002). The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J 196:254-65.
6. Bolat F, Kayaselcuk F, Nursal T.Z., et al. (2006). Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res 25:365-72.
7. Chen JJ, Lin YC, Yao P.L., et al. (2005). Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23: 953-64.
8. Condeelis J, Pollard JW (2006). Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263-6.
9. Deininger MH, Meyermann R, Schluesener HJ (2003). Expression and release of CD14 in astrocytic brain tumors. Acta Neuropathologica 106:271-7.
10. Gazzaniga S, Bravo AI, Guglielmotti A, et al (2007). Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 127:2031-41.
11. Giraudo E, Inoue M, Hanahan D. (2004). An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Investig 114:623-33.
12. Goswami S, Sahai E, Wyckoff J.B., et al. (2005). Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 65:5278-83.
13. Hamilton JA (2008). Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8:533-44.
14. Hattori Y, Sakaguchi M, Maitani Y. (2006). Folate-linked lipid-based nanoparticles deliver a NFkappaB decoy into activated murine macrophage-like RAW264.7 cells. Biol Pharm Bull 29:1516-20.
15. Kagaya T, Nakamoto Y, Sakai Y., et al. (2006). Monocyte chemoattract-ant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Ther 13:357-66.
16. Kobayashi N, Miyoshi S, Mikami T., et al. (2010). Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascu-larization. Cancer Res 70:7073-83.
17. Kono Y, Kawakami S, Higuchi Y., et al. (2014). In vitro evaluation of inhibitory effect of nuclear factor-kappaB activity by small interfering RNA on pro-tumor characteristics of M2-like macrophages. Biol Pharm Bull 37:137-44.
18. Lee MV, Fong EM, Singer F.R., Guenette RS. (2001). Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-8.
19. Marra M, Salzano G, Leonetti C., et al. (2011). Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine 7:955-64.
20. Nagai T, Tanaka M, Tsuneyoshi Y., et al. (2009). Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunol Immunother 58:1577-86.
21. Ottewell PD, Monkkonen H, Jones M., et al, (2008). Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100:1167-78.
22. Pollard JW. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71-8.
23. Rogers MJ, Gordon S, Benford H.L., et al. (2000). Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88: 2961-78.
24. Ross JR, Saunders Y, Edmonds P.M., et al. (2004). A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 8:1-176.
25. Senaratne SG, Pirianov G, Mansi J.L., et al. (2000). Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-68.
26. Shiokawa T, Hattori Y, Kawano K., et al. (2005). Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability and antitumor effect in vitro and in vivo. Clin Cancer Res 11:2018-25.
27. Shipman CM, Rogers MJ, Apperley J.F., et al. (1997). Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98:665-72.
28. Shmeeda H, Amitay Y, Tzemach D., et al. (2013). Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity. J Control Release 167:265-75.
29. Sica A, Rubino L, Mancino A., et al. (2007). Targeting tumour-associated macrophages. Expert Opin Ther Targets 11:1219-29.
30. Smith AE, Pinkney M, Piggott N.H., et al. (2007). A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues. Hybridoma 26:281-8.
31. Thompson K, Rogers MJ, Coxon F.P., Crockett JC. (2006). Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 69:1624-32.
32. Wollack JB, Makori B, Ahlawat S., et al. (2008). Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. J Neurochem 104:1494-503.
33. Yamada A, Taniguchi Y, Kawano K., et al. (2008). Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin Cancer Res 14:8161-8.
34. Zeisberger SM, Odermatt B, Marty C., et al. (2006). Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95:272-81.
35. Zhang W, Zhu XD, Sun H.C., et al. (2010). Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 16:3420-30.